Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Voyager Therapeutics

- PMLiVE

Novartis brings creative malaria campaign to Pinterest

Invites users to create their own mosquito-killing story

Novartis day

FDA needs more time to review Novartis’ cancer drug

Panobinostat is being investigated for use in multiple myeloma

- PMLiVE

Novartis partners with NHS on eye service

Launches community programme in Bristol

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

Novartis gets EU nod for rare disease drug Signifor

Long-acting formulation of drug approved for growth disorder acromegaly

- PMLiVE

NICE wants more info on Novartis’ Xolair in chronic hives

Says company must provide more data on the drug's effectiveness

Novartis building

Novartis to deliver three million malaria treatments in Zambia

Part of Malaria No More’s Power of One campaign

Novartis building

Novartis faces FDA rejection for myeloma drug

Concerns over toxicity of panobinostat

- PMLiVE

Pfizer gets FDA nod for meningitis vaccine Trumenba

Ahead of Novartis’ rival drug Bexsero

Novartis building

Novartis sells flu vaccines business to CSL for $275m

Follows the Swiss pharma company's asset swap deals with GSK

Novartis building

FDA panel backs Novartis’ secukinumab for psoriasis

Drug has outperformed Amgen’s Enbrel in clinical trials

Novartis building

Novartis’ secukinumab has ‘consistent’ activity in psoriasis

Reinforces data that suggests drug is more effective than Amgen’s Enbrel

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links